It is well established that tumor necrosis factor-α (TNFα) plays a central role in both the pro-inflammatory and apoptotic responses to endotoxemic shock. 1,2 However, Galanos and Freudenberg demonstrated several years ago that transcriptional inhibition in the liver with Dgalactosamine (D-GalN) dramatically increased the sensitivity of mice to the lethal effects of lipopolysaccharide (LPS). 3 More recent studies have shown that, unlike the response to high-dose LPS, D-GalN sensitization and low-dose LPS administration produces mortality through a significant apoptotic injury to the liver. 4 These effects are thought to result from the inhibition of NF-κB dependent survival gene transcription and translation. 3 D-GalN selectively blocks transcription in hepatocytes by depleting uridine nucleotides necessary for the production of mRNA transcripts. 5 Therefore, treatment with LPS in conjunction with D-GalN results in acute liver apoptosis and liver failure. 4, 6 The mechanisms by which TNF-α mediates this apoptotic liver injury remain unresolved. TNF-α can exist as both a cell-associated (membrane-bound) and secreted protein, and can transduce its signal by binding to one of two cellular receptors, type I (p55) or type II (p75). 7 Although it has been generally presumed that the proinflammatory properties of TNF-α are primarily due to secreted TNF-α signaling through the p55, and not p75
INTRODUCTION
receptor, [8] [9] [10] studies by Kollias and colleagues 11, 12 and Grell et al. 13 have suggested that cell-associated TNF-α signaling through the p75 receptor may also play a contributory role in hepatocyte apoptosis. These investigators have shown that the liver injury secondary to concanavalin A treatment is not due solely to secreted TNF-α acting through the p55 receptor, but is also the result of cell-associated TNF-α signaling through the p75 receptor. 12 The present report summarizes experimental data obtained over the past several years where we have used a genetic approach to resolve the relative contributions of secreted and cell-associated TNF-α, and p55 and p75 receptor signaling, to the lethality and hepatic injury secondary to LPS and D-GalN. We have employed mice expressing null forms of TNF-α, the p55 and p75 receptor, FasL, and mice expressing only a cell-associated form of TNF-α. In addition, we have noted a significant variation in the responsiveness to LPS and D-GalN among different strains of mice, including the NOD and NZW mouse which are highly resistant to the lethal effects of LPS and D-GalN. The results obtained to date clearly demonstrate that lethality to LPS in the D-GalN sensitized mouse is due primarily to secreted TNF-α signaling through the p55 receptor and activating caspase-3 dependent apoptotic pathways in the liver.
MATERIALS AND METHODS

Mice and reagents
C57BL/6 (B6) and NOD/Ltj (NOD) mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA) or from the Department of Pathology Animal Resource Facility, University of Florida College of Medicine. NOD and B6 mice bred at the University of Florida were derived from breeding stock obtained from The Jackson Laboratory. B6 mice expressing a null form of the TNF receptor type I (p55) or TNF receptor type II (p75) (p55 -/or p75 -/-, respectively) were obtained from Amgen, Inc. (Thousand Oaks, CA, USA) or Immunex, Inc. (Seattle, WA, USA), respectively. 8 TNF-α (tnf -/-) null mice were obtained from Amgen, Inc., and were on a B6 x 129 background. B6Smn.C3H-Fasl gld were obtained from The Jackson Laboratory. Mice expressing only a transmembrane, non-cleavable cell-associated form of TNF-α (tnf -/-× tnf tgA86 ) 11 were also obtained from Amgen, Inc. Appropriate wild-type B6 × 129 mice were also employed for these studies and were bred in-house at the University of Florida SPF transgenic mouse facility (Gainesville, FL, USA). All protocols were approved by the Institutional Animal Care and Use Committee of the University of Florida College of Medicine.
Experimental model
All mice received intraperitoneal injections of 8 mg of D-GalN, and 100 ng of LPS (Escherichia coli, serotype O111:B4). Some additional mice received recombinant human TNF-α (10 µg) instead of LPS. The dose of LPS or TNF-α and D-GalN was based on ~90% mortality by 48 h in wild-type mice.
At 90 min, mice were either bled retro-orbitally for determination of plasma TNF-α bioactivity, or were sacrificed by cervical dislocation for determination of liver membrane TNF-α bioactivity. At 6 h, additional mice were killed, and livers harvested for histological analysis. Plasma GOT/AST concentrations were measured using a commercial diagnostic kit (Sigma Diagnostics, St Louis, MO, USA). A third group of mice were treated and survival evaluated over 48 h.
Histological examination
Livers were fixed in 3% buffered formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin for morphological changes, and additional sections were processed for immunostaining of apoptotic nuclei using the Apotag™ kit (Oncor, Inc., Gaithersburg, MD, USA) as described by the manufacturer.
TNF-α bioactivity
Freshly obtained sections of livers were homogenized, and assayed for membrane TNF-α as previously described. 2 Plasma and liver membrane TNF-α bioactivity were determined using the WEHI cytotoxicity assay. 14 
Liver caspase-3-like activity assay
Livers were homogenized in three volumes (v/w) of icecold homogenization buffer (25 mM HEPES, pH 7.5, 5 mM MgCl 2 , 1 mM EDTA, 1 mM PMSF, 1 µg/ml leupeptin and 1 µg/ml aprotinin). Homogenates were centrifuged at 13,500 rpm in a Beckman J2-HS centrifuge for 15 min and supernatants assayed for protein content using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA) according to kit instructions. Liver homogenates were assayed for caspase-3-like activity using protocols previously described. 15 
RESULTS
Results have been summarized from several recent publications. 1, [16] [17] [18] Wild-type B6 and B6 x 129 mice were exquisitely sensitive to the lethal effects of LPS when the sensitizing agent D-GalN was employed. Lethality was close to 100% and animals expired within 48 h. Representative animals were sacrificed at 90 min to measure peak TNF-α concentrations, and at 6 h to assess the degree of apoptotic liver damage. As summarized in Figure 1 , the response can be characterized by an initial appearance of liver and plasma TNF-α, followed by increased hepatic caspase-3 activity, appearance of large areas of focal necrosis in the liver and widespread hepatocyte apoptosis (Fig. 2) , increases in the serum concentration of liver specific enzymes and ultimately death of the animals.
There is an obligatory requirement for TNF-α in this model of apoptotic liver injury. Mice expressing a null form of TNF-α were completely resistant to the lethal effects of the LPS and D-GalN (Fig. 3 ). These animals also manifested much reduced increases in liver specific enzymes (Fig. 4) , and had markedly reduced numbers of apoptotic hepatocytes. Surprisingly, mice expressing only a cell-associated form of TNF-α (TgA 86 ) were also protected from lethality and had only modest increases in liver specific enzymes and hepatocyte apoptosis. These latter findings suggest that only the secreted and not the cell-associated form of TNF-α contributes to mortality in this model. In contrast to TNF-α, mice Genetic determinants to hepatocyte apoptosis 377 Not only is secreted TNF-α required for hepatic injury and mortality, but intact signaling through the type I (p55) receptor is also required. Mice expressing a null form of the p55, but not the p75 receptor, were completely protected from the lethal effects of LPS and D-GalN. In addition, p55 null mice also exhibited much more modest increases in serum AST concentrations, and reduced areas of hepatocyte apoptosis. In contrast, p75 null mice tended to have exaggerated liver injuries and a worsened outcome. Such findings suggest that TNF-α signaling through the p55 receptor is required.
Finally, we have noted that some strains of mice are much more resistant to the lethal effects of LPS and D-GalN than are the B6 or B6 x 129 mouse. In a recent report, we examined the administration of 8 mg of D- Fig. 3 . Survival responses in transgenic mice treated with LPS and D-GalN. Mice were treated with LPS and D-GalN and survival was followed for 48 h. Wild-type, B6Smn.C3H-Fasl gld and p75 knockout mice had significant mortality, whereas TNF-α, p55 and TgA86 mice were protected from lethality. Data from Josephs et al. 16 and Nowak et al. 17 Fig. 4 . Liver AST responses in transgenic mice treated with LPS and D-GalN. Wild-type, B6Smn.C3H-Fasl gld and p75 knockout mice had significant liver injury, whereas TNF-α, p55 and TgA86 mice were protected. Data from Josephs et al. 16 GalN and increasing amounts of LPS to the NOD mouse. 18 These animals were highly resistant to the lethal effects of LPS and D-GalN (Fig. 5) , and have much lower levels of caspase-3 activation in the liver and hepatocyte apoptosis. This appeared to be due to a signal transduction defect in the p55 receptor since administration of human TNF-α (which binds only to the mouse p55 receptor) in the presence of D-GalN also did not produce the lethality and hepatocyte injury seen in the B6 mouse. The resistance to TNF-α-induced lethality in this model appeared to be due to a post-TNF receptor defect, since binding of biotinylated human TNF-α (a ligand for the murine p55 receptor) to murine splenocytes or recruited peritoneal macrophages was not defective in the NOD mouse. 18 
DISCUSSION
Recent studies have more fully clarified the contribution of cell-associated and secreted TNF-α and their signaling by the two TNF receptors (p55 and p75) to the lethality and apoptotic hepatic injury associated with LPS and D-GalN administration. Mortality from LPS and D-GalN appears to result from a fulminant liver injury characterized by widespread apoptotic death of hepatocytes. 19 In this regard, the model differs significantly from the administration of high-dose LPS (5-20 mg/kg body weight) alone which produces only minimal hepatocyte apoptosis, but significant necrotic injury. 19 In addition, the model is dramatically different from the Corynebacterium parvum model of sensitization to the lethal effects of LPS or TNF-α associated with activation of Kupffer cells and liver infiltrating T-and NKcells. Unlike these other models, lethality from LPS and D-GalN treatment is dependent on caspase-mediated apoptotic liver injury, as demonstrated by the ability of synthetic caspase inhibitors to the block the apoptosis seen in mice treated with LPS and D-GalN. 4, 20 However, these inhibitors did not prevent lethality to high-dose LPS, nor did they block the early inflammatory responses to LPS and D-GalN treatment, indicating that toxicity in this model is independent of the systemic inflammatory response. 4 It has been well established by Wendel and colleagues that TNF-α plays a central role in the pathology of LPSand D-GalN-induced lethality, 21 but less is known regarding the role of cell-associated and secreted TNF-α signaling though its two receptors in the development of apoptotic hepatic injury. The present results are unequivocal in demonstrating that the lethality to LPS and D-GalN is exclusively dependent upon secreted TNF-α signaling through the p55 receptor. The observation that p55 receptor signaling is required for lethality is already well established, 8, 22, 23 as is the requirement for TNF-α. 24 The current findings can now confirm that secreted TNF-α and not cell-associated TNF-α is the primary species responsible for this lethality.
Similarly, the results suggest that FasL plays no significant role in outcome. We have previously shown that FasL expression is increased in the liver following endotoxin administration. 25 However, in this model, expression of a defective FasL failed to abrogate the mortality or liver injury. These findings diverge from the conclusions reached by Nagata and colleagues. Kondo and Nagata reported that blocking an endogenous FasL response with soluble Fas fusion proteins protected against liver injury in a C. parvum and lipopolysaccharide shock model. 26 In their studies, blockade of FasL was as effective as TNF-α blockade in preventing liver injury and mortality. However, Morikawa et al. have reported that lpr mice lacking functional CD95 (Fas) were not resistant to D-GalN/LPS-induced lethality and hepatic apoptosis, consistent with the observations reported here. 6 In addition, we have observed that the NOD mouse is particularly resistant to the lethal effects of LPS or rhTNF-α and D-GalN. Previous studies have shown that this may be a post-receptor defect since TNF-α binds to the NOD p55 receptor with the same affinity as it does to the B6 p55 receptor. 18 Furthermore, we have shown that the NOD mouse remains sensitive to FasL induced apoptosis, since administration of the Fas agonist Jo-2 produces significant lethality. The observation that the levels of caspase-3-like activity in the livers of NOD mice treated with LPS or TNF-α and D-GalN were markedly reduced, but not absent, suggests that the defect occurs distal to TNF-α binding to the p55, but proximal to or at the level of activation of caspase-3.
The observation that NOD mice are resistant to the hepatocyte injury and lethality associated with p55 receptor signaling has significant implications for other p55 receptor-dependent processes, such as apoptosis of lymphoid cell populations. In addition, it raises the potential question of whether polymorphisms in the response to LPS-and TNF-α-induced hepatocyte apoptosis may also exist in human populations, as they do in mouse strains. Although polymorphisms have been seen in the promoter for TNF-α/TNF-β, 27 few investigations have examined whether polymorphisms in TNF-α signaling pathways exist in humans, similar to that seen in mice. The current studies confirm the value of the LPS and D-GalN model to study TNF-α and p55 receptor signaling pathways in hepatocyte apoptosis.
